Scientists at the University of Oxford plan to begin a UK-based Ebola vaccine trial “within weeks,” according to reports. The study is designed to test the vaccine’s ability to build immunity in participants, with initial recruitment focused on 50 adults in the United Kingdom. The trial is described as a “world-first” effort in the available coverage, though specific comparative details of how it is “world-first” are not provided in the excerpts. The reporting also refers to an ongoing Ebola outbreak and states that the number of fatalities is rising, adding urgency to the development and testing timeline. Across the sources, the central points are the planned start date in the near term, the adult participant count, and the purpose of building immune protection against Ebola. The articles do not, in the provided text, offer further information about trial phases, eligibility criteria, vaccine type, regulatory approvals, or expected follow-up schedules.